Table 2.
The Relation between the Percentages of the Positive Samples for SPAG9 Gene Expression and Clinicopathological Data at Diagnosis
| SPAG9 expression percentage | ||||
|---|---|---|---|---|
| Clinical Factor | Number of cases | - | + | P-value |
| Gender | Male (n=27) | 26 | 74 | |
| Female (n=34) | 28 | 62 | 0.412 | |
| Age (years) | >50 (n=39) | 31 | 69 | |
| ≤50 (n=21) | 38 | 62 | 0.579 | |
| T category (A) | TX (n=2) | 100 | 0 | |
| T1 (n=5) | 20 | 80 | ||
| T2 (n=14) | 43 | 57 | 0.261 | |
| T3 (n=30) | 33 | 67 | ||
| T4 (n=9) | 22 | 78 | ||
| T category (B) | TX & T1 & T2 (n= 21) | 41 | 59 | |
| T3 & T4 (n=39) | 32 | 68 | 0.577 | |
| Relapse | + (n=43) | 46 | 54 | |
| - (n=13) | 33 | 67 | 0.51 | |
| N category (A) | N0 (n=31) | 39 | 61 | |
| N1 (n=22) | 27 | 73 | 0.686 | |
| N2 (n=9) | 33 | 67 | ||
| N category (B) | N0 (n=30) | 40 | 60 | |
| N1 & N2 (n=31) | 30 | 70 | 0.426 | |
| M category | M0 (n=51) | 31 | 69 | |
| M1 (n=11) | 45 | 55 | 0.485 | |
| Tumor Size (centimeters) | 1.5-3 (n=22) | 36 | 64 | |
| 3.1-5.5 (n=19) | 32 | 68 | 0.948 | |
| 5.6-12 (n=20) | 35 | 65 | ||
| Stage | Stage 0 (n=6) | 33 | 67 | |
| Stage 1 (n=14) | 36 | 64 | ||
| Stage 2 (n=19) | 47 | 53 | 0.504 | |
| Stage 3 (n=16) | 25 | 75 | ||
| Stage 4 (n=7) | 14 | 86 | ||
p* < 0.05 significance association between gene expression and clinical risk factors; T category, The rate of growth and progression of tumors in the intestinal wall layers based on the pathological division; M, Metastasis to other organs (M0: non metastatic, M: metastatic); N, Lymph node involvement (N0: no involvement); Tumor Size, The length of tumors in centimeters; Relapse, Tumor Recurrence (+: Recurrence, -: no Recurrence); Stage, Stage of cancer according to TNM classification System and pathological data.